Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05009927
PHASE2

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

Sponsor: Centre Leon Berard

View on ClinicalTrials.gov

Summary

This is a 2 arms study concerning patients under imatinib treatment for at least 10 years of treatment with locally advanced/metastatic GIST. In the first arm, patients will discontinue Imatinib treatment. This arm will allow to determine if the re-introduction of Imatinib at relapse is still an efficient treatment for the control of disease. In the second arm, patients will continue Imatinib treatment, allowing to determine if the continuation of this treatment is efficient for disease control, by the rate of non-progression disease.

Official title: Randomized, Multicentre, Phase II Study Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After at Least 10 Years of Treatment in Patients With Locally Advanced/Metastatic Gastrointestinal Stromal Tumors (GISTs)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2022-01-03

Completion Date

2027-01

Last Updated

2023-09-01

Healthy Volunteers

No

Interventions

DRUG

Imatinib tablets

Imatinib interruption

Locations (13)

CHU Besançon

Besançon, France

Institut Bergonié

Bordeaux, France

CHU Dupuytren

Limoges, France

Centre Léon Bérard

Lyon, France

Institut Paoli Calmettes

Marseille, France

Institut Curie

Paris, France

CHU de Reims

Reims, France

Centre Eugène Marquis

Rennes, France

Institut de Cancérologie de l'Ouest - Site Réné Gauducheau

Saint-Herblain, France

Institut de Cancérologie Lucien NEUWIRTH

Saint-Paul-en-Jarez, France

Institut Claudius Regaud

Toulouse, France

Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, France

Institut Goustave Roussy

Villejuif, France